What Are PCSK9 Inhibitors?
PCSK9 inhibitors have revolutionised the treatment of hyperlipidaemia and atherosclerotic cardiovascular disease.
PCSK9 (Proprotein convertase subtilisin/kexin type 9 ) is a protein that regulates the amount of harmful LDL cholesterol receptors you have in your liver. The higher the PCSK9 level, the higher the LDL.
Inclisiran is a monoclonal antibody that inhibits the production of PCSK9, which in turn increases the liver’s ability to remove harmful LDL-cholesterol from the body.
By doing this, it dramatically reduces LDL cholesterol, triglycerides, Apolipoprotein B, and lipoprotein(a).
Who Should Consider PCSK9 Inhibitors?
Inclisiran is licensed for hypercholesterolaemia, one of the biggest risk factors in developing atherosclerotic cardiovascular disease.
This is especially important:
• When LDL levels are high.
• When there is a strong family history of cardiovascular disease.
• When there are other cardiovascular risk factors such as hypertension and obesity.
• When statins do not work to reduce LDL enough or are not tolerated due to side effects.
This applies even in the absence of pre-existing heart disease, aortic aneurysms, strokes, or peripheral vascular disease.
Benefits of PCSK9 Inhibitors
– Large randomised controlled trials have shown a 50-60% reduction in LDL, cutting the risk of a heart attack by almost a quarter.
– There is emerging evidence suggesting that PCSK9 inhibitors have beneficial effects on longevity, with ongoing studies to confirm these findings.
– After the initial dose, Inclisiran is administered once at 3 months and then one injection every 6 months, eliminating the daily need for a statin.
Risks of PCSK9 Inhibitors?
Inclisiran was approved for use in 2021 after clinical trials involving thousands of participants. It has been found to be safe for over six years, with no documented long-term harmful effects. The most common side effect is localised injection site reactions, such as redness, swelling, or itching.
Optimising Cardiovascular Health and Longevity
Inclisiran provides a highly effective, well-tolerated alternative for individuals seeking to reduce LDL cholesterol and lower cardiovascular risk. For those focused on longevity and preventative health, PCSK9 inhibitors offer a promising solution that is both effective and convenient.
For Further Scientific Reference: Efficacy and Safety of Inclisiran in Patients
Learn More About Our Preventative Health Assessments
Discover the Latest Advances in Longevity Medicine
